India's Unichem Labs jumps on U.S. FDA nod to market AstraZeneca antidepressant

Unichem Laboratories

20/05/2021 10:41

** Indian drugmaker's shares  UNLB.NS  rise as much as 9.6%
to 364.20 rupees in afternoon trade - hits highest level in more
than 3 years
    ** Unichem Laboratories got the U.S. drug regulator's
approval to market a generic version of Elavil, AstraZeneca's
treatment for depression  urn:newsml:reuters.com:*:nBSEbXG1KC
    ** Co will commercialize the product in 6 doses at its plant
in Goa state
    ** According to an article https://www.thelancet.com/pdfs/journals/lanpsy/PIIS2215-0366(19)30475-4.pdf
 published in medical journal The Lancet, one in seven Indians
was affected by mental disorders of varying severity in 2017,
with high prevalence of depression among older adults
    ** UNLB shares set for best day in about a year, if gains
hold
    ** Including session's gains, stock up over 38% YTD

 (Reporting by Shivani Singh in Bengaluru)
 ((ShivaniSingh1@thomsonreuters.com; +91 89 6969 2349))